

PLATINUM INT'L HEALTH CARE FUND ARSN 107 023 530

31 May 2013

FACTS

Portfolio Value \$62.31 mn

Fund commenced 10 November 2003 Minimum investment A\$20,000 or NZ\$25,000 A\$200 or NZ\$250 per mth/qtr

Regular Investment Plan (min.) Income distribution date

Annual, 30 June Sydney Business Day

Unit valuation **Unit prices**

App 1.4337 Red 1.4265

Entry fee Nil Exit fee Nil

Management Expense Ratio/ Indirect Cost Ratio (MER/ICR) 1.54% per annum (inclusive of investment &

administration costs)


Brokerage paid Nil Buy/sell spread 0.5% total

PERFORMANCE ¹		
	FUND %	MSCI %
1 month	7.66	8.15
3 months	8.94	17.00
6 months	21.05	29.46
1 year	32.55	37.72
2 years (compound pa)	17.05	21.36
3 years (compound pa)	15.53	14.73
5 years (compound pa)	11.74	9.30
7 years (compound pa)	6.60	3.92
Since inception (compound pa)	6.37	5.13

3 months		8.94	17.00
6 months		21.05	29.46
1 year		32.55	37.72
2 years (compound pa)		17.05	21.36
3 years (compound pa)		15.53	14.73
5 years (compound pa)		11.74	9.30
7 years (compound pa)		6.60	3.92
Since inception (c	ompound pa)	6.37	5.13
INVESTED POSI	TION ³		
	LONG %	NET %	CURRENCY %
Australia	1.7	1.7	1.7
Belgium	2.5	2.5	

	LONG %	NET %	CURRENCY %
Australia	1.7	1.7	1.7
Belgium	2.5	2.5	
Brazil	1.6	1.6	1.6
Denmark	4.8	4.8	4.8
France	5.8	5.8	
Germany	5.6	5.6	
Italy	4.7	4.7	
Japan	3.1	3.1	4.0
Sweden	4.1	4.1	4.1
Switzerland	10.3	10.3	7.8
UK	7.2	7.2	7.3
US	26.4	24.7	33.9
Total	77.8	76.1	
Canadian \$			2.1
Euro			22.3
HK\$			3.8
Korean Won			1.7
Norwegian Krone			1.3
Singapore \$			3.6
Cash & Accruals	22.2	23.9	
Total	100.0	100.0	100.0

Long - 47 stocks Short - 1 Index



Source: Factset and Platinum

TOP TEN POSITIONS ⁴				
<u>STOCK</u>	COUNTRY	<u>INDUSTRY</u>	<u>%</u>	
Sanofi SA	France	Pharmaceuticals	3.6	
Novartis AG	Switzerland	Pharmaceuticals	3.0	
Teva Pharmaceuticals	United States	Pharmaceuticals	2.8	
Genmab A/S	Denmark	Pharmaceuticals	2.7	
Qiagen NV	Germany	Health Equip & Servs	2.6	
Gilead Sciences Inc	United States	Biotechnology	2.5	
Roche Holding AG	Switzerland	Pharmaceuticals	2.5	
AstraZeneca PLC	United Kingdom	Health Equip & Servs	2.4	
Ipsen SA	France	Pharmaceuticals	2.3	
Immunogen Inc	United States	Biotechnology	2.3	
ILIDIIOTRY DREAMS	O11/01/2			

INDUSTRY BREAKDOWN ³		
SECTOR	LONG %	NET %
Pharmaceuticals	41.6	41.6
Health Equipment & Services	13.6	13.6
Biotechnology	12.0	12.0
Misc Manufacturing	3.6	3.6
Healthcare Providers	3.5	3.5
Chemicals	1.8	1.8
Electrical Equipment	1.7	1.7
Equity Funds*		(1.7)
*Includes index short position		

1. Investment returns are calculated using the Fund's unit price and represent the combined income and 1. Investment returns are calculated using the rund's unit price and represent the combined income and capital return for the specified period. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax, and assume the reinvestment of distributions. The investment returns shown are historical and no warranty can be given for future performance. You should be aware that historical performance is not a reliable indicator of future performance. Due to the volatility of underlying assets of the Fund and other risk factors associated with investing, investment returns can be negative (particularly in the short-term).

2. The investment returns depicted in this graph are cumulative on A\$20,000 invested in the Fund since inception relative to the MSCI All Country World Health Care Net Index in A\$. The investment returns are calculated using the Fund's unit price. They are net of fees and costs (excluding the buy-sell spread and any investment performance fee payable), pre-tax and assume the reinvestment of distributions. It should be noted that Platinum does not invest by reference to the weightings of the Index. Underlying assets are chosen through Platinum's individual stock selection process and as a result holdings will vary considerably to the

make-up of the Index. The Index is provided as a reference only.

3. The "Long %" represents the exposure of physical holdings and long stock derivatives. The "Net %" represents the exposure of physical holdings and both long and short derivatives.

The "Currency %" represents the currency exposure for the Fund's Portfolio, taking into

account currency hedging.

4. Top Ten positions shows the Fund's top long share exposure positions. Long derivative exposures are included, however, short derivative exposures are not

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935, trading as Platinum Asset Management (Planiement Limited Aby 25 005 356 006 Arts). Z21935, trading as Platinum Asset Management (Platinum) is the responsible entity and issuer of units in the Platinum Int'l Health Care Fund (the Fund). The Platinum Trust Product Disclosure Statement No.8 and Supplementary PDS (together PDS) provides details about the Fund. You can obtain a copy of the PDS from Platinum's website, www.platinum.com.au, or by contacting Investor Services on 1300 726 700 (Australian investors only), 0800 700 726 (New Zealand investors only), or 02 9255 7500, or via Invest@platinum.com.au

Invest@platinum.com.au. Before making any investment decision you need to consider (with your financial adviser) your particular investment needs, objectives and financial circumstances. You should refer to the PDS when deciding to acquire, or continue to hold, units in the Fund.

DISCLAIMER: The information presented in this Fact Sheet is not intended to be advice. It has not been prepared taking into account any particular investor's or class of investor's investment objectives, financial situation or needs, and should not be used as the basis for making investment, financial or other decisions. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. Platinum does not for any loss or damage as a result of any reliance on this information. Platinum does not guarantee the repayment of capital, payment of income or the Fund's performance. Platinum is a member of the Platinum Group of companies.